Estudio RAINBOW:
Características pacientes
Characteristic
Group 4:2
→
2:1 (n=208)
Group 2:1 (n=41)
Control Group (n=211)
Age, yr
Median (range)
62 (25–82)
61 (32–82)
59 (28–86)
Gender – no. (%)
Male
149 (71.6)
(
)
26 (63.4)
(
)
164 (77.7)
(
)
Female
59 28.4
15 36.6
47 22.3
ECOG PS – no. (%)
0
1
2 or more
152 (73.1)
52 (25.0)
4 (1.9)
24 (58.5)
15 (36.6)
2 (4.9)
203 (96.2)
8 (3.8)
‐
Histotype – no. (%)
Clear cell
Papillary
Chromophobe
Unknown or missing
197 (94.7)
7 (3.4)
2 (1.0)
2 (1.0)
36 (87.8)
3 (7.3)
2 (4.9)
‐
183 (86.7)
22 (10.4)
5 (2.4)
1 (0.5)
Heng prognostic classification – no.(%)
Favorable risk
88 (42.3)
10 (24.4 )
72 (34.1)
Intermediate risk
Poor risk
109 (52.4)
11 (5.3)
27 (65.8)
4 (9.8)
128 (60.7)
11 (5.2)
Lung involvement – no. (%)
No
Yes
84 (40.4)
124 (59.6)
14 (34.1)
27 (65.9)
73 (34.6)
138 (65.4)
Bone involvement no (%)
– .
No
Yes
163 (78.4)
45 (21.6)
30 (73.2)
11 (26.8)
157 (74.4)
54 (25.6)
Liver involvement – no. (%)
No
Yes
176 (84.6)
32 (15.4)
30 (73.2)
11 (26.8)
170 (80.6)
41 (19.4)
CNS involvement – no. (%)
No
Yes
200 (96.2)
8 (3.8)
37 (90.2)
4 (9.8)
203 (96.2)
8 (3.8)
Bracarda S et al, Ann Oncol. 2015
